Status:

COMPLETED

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

Lead Sponsor:

Hellenic Oncology Research Group

Collaborating Sponsors:

University Hospital of Crete

Conditions:

Breast Cancer

Eligibility:

FEMALE

18-75 years

Phase:

PHASE3

Brief Summary

Anthracycline-containing regimens are recommended as adjuvant treatment for women with node positive breast cancer. In at least three large randomized clinical trials the addition or sequential admini...

Detailed Description

This trial will compare the dose dense, G-CSF supported sequential administration of 4 cycles of 5-Fluoruracil (F) plus Epirubicin (E 75mg/m2) plus Cyclofosfamide (C) followed by 4 cycles of docetaxel...

Eligibility Criteria

Inclusion

  • Women with histologically-confirmed unilateral invasive ductal or lobular breast adenocarcinoma
  • Within 60 days after the surgical excision of the primary tumor with tumor-free operation margins; at least 10 axillary lymph nodes have to be removed.
  • Tumor involvement of at least one axillary lymph node
  • Absence of any clinical or radiological evidence of local or metastatic disease
  • Premenopausal or postmenopausal women aged 18-75 years old
  • Adequate bone marrow function (absolute neutrophil count \>1500/mm3, platelet count \>100.000/mm3, hemoglobin \>10gr/mm3)
  • Adequate liver (bilirubin \<1.0 times upper limit of normal and SGOT/SGPT \<2.5 times upper limit of normal) and renal function (creatinine \<1.5mg/dl)
  • Adequate cardiac function (LVEF\>50%)
  • Written informed consent

Exclusion

  • Positive pregnancy test.
  • Psychiatric illness or social situation that would preclude study compliance.
  • Other concurrent uncontrolled illness.
  • Prior or concurrent antineoplastic therapy e.g. hormonal therapy, radiation therapy, chemotherapy, biological agents.
  • Previous history of other invasive malignancy other than non-melanomatous skin cancer.

Key Trial Info

Start Date :

August 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2007

Estimated Enrollment :

478 Patients enrolled

Trial Details

Trial ID

NCT00431080

Start Date

August 1 2004

End Date

October 1 2007

Last Update

January 21 2008

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

University Hospital of Crete

Heraklion, Crete, Greece, 71110

2

University General Hospital of Alexandroupolis, Dep of Medical Oncology

Alexandroupoli, Greece

3

"IASO" General Hospital of Athens, 1st Dep of Medical Oncology

Athens, Greece

4

"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine

Athens, Greece